



Synlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

September 20, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Synlogic's president and chief executive officer, will present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at 4:00 p.m. ET on Wednesday, September 27, 2017, in New York City.

A live webcast of the presentation can be accessed under "[Event Calendar](#)" in the Investors & Media section of the Company's website. An archived webcast recording will be available on the Synlogic website for approximately 30 days after the event.

About Synlogic:

Synlogic is pioneering the development of a novel class of living treatments, Synthetic Biotic™ medicines, based on its proprietary drug development platform. Synlogic's initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170920006089/en/>

Source: Synlogic

MEDIA CONTACT:

Synlogic

Courtney Heath, 617-872-2462

courtney@scientpr.com

or

INVESTOR CONTACT:

Synlogic

Elizabeth Wolffe, Ph.D., 617-207-5509

liz@synlogictx.com